JOURNAL REPRINTS THAT REFERENCE UNAPPROVED USES ALLOWED UNDER FDA PROMOTION REFORM; TEXTBOOK DISSEMINATION PERMITTED IF OFF-LABEL USE NOT "HIGHLIGHTED"
This article was originally published in The Gray Sheet
Executive Summary
FDA will allow companies to disseminate journal reprints of studies used to support an approved indication that include incidental references to off-label uses, the agency says in a Nov. 21 Talk Paper."
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.